RM

Rama Mangeswar Reddy Bobbiti

Active Director Managing Director DIN 03468091
DIN 03468091 First appointment Oct 2011 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 2 active board seats
Past companies 2 historical roles
Total affiliations 4 Since Oct 2011
Shareholding value •••• Premium profile

About Rama Mangeswar Reddy Bobbiti

Data last updated:

Rama Mangeswar Reddy Bobbiti is a Managing Director at Shreegen Pharma Limited (since 2012) and Director at Syngreen Lifesciences Private Limited (since 2021). The companies operate in Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹9.30 Cr; the largest is Shreegen Pharma Limited at ₹9.20 Cr (FY 2023). Earlier, Rama Mangeswar Reddy Bobbiti was a Director at Hakue Labs Private Limited (2014–2016) and Additional Director at Carmol Drugs Private Limited (2011–2012).

DIN 03468091
Primary Designation Managing Director
Industry Pharma
First Appointment 31 Oct 2011
Oldest Company Age 14 yrs
Largest company Shreegen Pharma Limited · ₹9.20 Cr (FY 2023)
Combined revenue ₹9.30 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Shreegen Pharma Limited U24233TG2012PLC083695
Managing Director18 Oct 20122012₹9.20 Cr (FY 2023)Active
Director08 Jul 20212021₹10.5 Lakh (FY 2025)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Hakue Labs Private Limited U73100KA2006PTC039126
Director11 Dec 20142006Active
Carmol Drugs Private Limited U24232TG2011PTC073378
Additional Director31 Oct 20112011Active

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Rama Mangeswar Reddy Bobbiti

Directorship timeline

Open interactive timeline →
Shreegen Pharma Limited
Syngreen Lifesciences Private Limited
Hakue Labs Private Limited
Carmol Drugs Private Limited
Premium access

Shareholding and investment profile for Rama Mangeswar Reddy Bobbiti

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rama Mangeswar Reddy Bobbiti

Rama Mangeswar Reddy Bobbiti currently holds 2 directorships: Shreegen Pharma Limited (Managing Director, since 18 Oct 2012, revenue ₹9.20 Cr (FY 2023)); Syngreen Lifesciences Private Limited (Director, since 08 Jul 2021, revenue ₹10.5 Lakh (FY 2025)).

Rama Mangeswar Reddy Bobbiti was first appointed on 31 Oct 2011 as Additional Director at Carmol Drugs Private Limited. The most recent appointment on record is 08 Jul 2021 at Syngreen Lifesciences Private Limited.

The 2 current companies of Rama Mangeswar Reddy Bobbiti that report revenue have a combined latest revenue of ₹9.30 Cr: Shreegen Pharma Limited ₹9.20 Cr (FY 2023); Syngreen Lifesciences Private Limited ₹10.5 Lakh (FY 2025).

Rama Mangeswar Reddy Bobbiti held 2 earlier board appointments: Hakue Labs Private Limited (Director, 11 Dec 2014 to 14 Jun 2016); Carmol Drugs Private Limited (Additional Director, 31 Oct 2011 to 01 Nov 2012).

The current boards of Rama Mangeswar Reddy Bobbiti's companies include Chandra Balireddy Kotthapalli (Shreegen Pharma Limited), Kanaka Nallamilli Sundara Reddy (Shreegen Pharma Limited), Rajeev Dinesh Srivastava (Shreegen Pharma Limited), Sishtla Ramakrishnan (Shreegen Pharma Limited), Srinivasa Reddy Daka (Shreegen Pharma Limited), Venkata Suryanarayana Reddy Chilukuri (Shreegen Pharma Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available